PMID- 35759244
OWN - NLM
STAT- MEDLINE
DCOM- 20220629
LR  - 20220716
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 10
IP  - 7
DP  - 2022 Jul
TI  - EBV protection- and susceptibility-related HLA alleles and EBV status in the 
      Chinese population: A single-center study.
PG  - e666
LID - 10.1002/iid3.666 [doi]
LID - e666
AB  - BACKGROUND: Although most adults are infected by Epstein-Barr virus (EBV), some 
      patients develop highly lethal diseases associated with EBV infection, including 
      EBV-hemophagocytic lymphohistiocytosis (EBV-HLH), chronic active EBV infections 
      (CAEBV), and lymphoma, the pathogeneses of which remain to be investigated. The 
      human leukocyte antigen (HLA) complex may be associated with the viral infection 
      pathway, and, therefore, HLA alleles may be associated with EBV-related diseases 
      and subpopulations of infected cells, studies related to EBV-associated diseases, 
      and subpopulations of infected cells that were conducted in China are scarce. 
      METHODS: In this study, we analyzed the high-resolution HLA genotypes of 269 
      patients with EBV-associated diseases and 213 EBV-seronegative hematopoietic stem 
      cell donors using PCR-SBT assay and elucidated the associations of HLA-A, -B, -C, 
      -DRB1, and -DQB1 alleles with EBV-associated diseases in the Chinese population, 
      Benjamini-Hochberg correction to adjust for multiple testing. HLA genotypes were 
      also analyzed in patients with EBV-associated diseases showing EBV-infected 
      lymphocyte subpopulations. RESULTS: We found that individuals carrying the 
      following alleles showed the following levels of risks: HLA-DRB1*11 allele, 
      reduced risk of EBV-related disease (OR [odds ratio]: 0.56; 95% confidence 
      interval [95% CI]: 0.32-0.99; p < .05; Adjust p = .71); HLA-DQB1*06:02 allele, 
      reduced risk (OR: 0.5699; 95% CI: 0.3486-0.9317; p < .05; Adjust p = .57); and 
      HLA-B*15:01 allele, increased risk (OR: 1.763; 95% CI: 0.3486-0.9317; p < .05; 
      Adjust p = .57). Patients with EBV-associated diseases showing the B*15:01 
      genotype had a higher risk of T-cell, NK-cell, and multicell infections than 
      those with other genotype subgroups. CONCLUSIONS: These findings highlight the 
      importance of HLA genotype for assessing EBV infectivity.
CI  - (c) 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & 
      Sons Ltd.
FAU - Suolitiken, Dina
AU  - Suolitiken D
AUID- ORCID: 0000-0002-1990-6158
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, People's Republic of China.
FAU - Wang, Yini
AU  - Wang Y
AUID- ORCID: 0000-0001-8545-2660
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, People's Republic of China.
FAU - Jin, Zhili
AU  - Jin Z
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, People's Republic of China.
FAU - Wang, Zhao
AU  - Wang Z
AD  - Department of Hematology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - *Epstein-Barr Virus Infections/genetics
MH  - HLA-A Antigens/genetics
MH  - HLA-B Antigens/genetics
MH  - *Herpesvirus 4, Human/genetics
MH  - Humans
PMC - PMC9210551
OTO - NOTNLM
OT  - EBV
OT  - HLA
OT  - infection
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/28 06:00
MHDA- 2022/06/30 06:00
PMCR- 2022/06/21
CRDT- 2022/06/27 11:26
PHST- 2022/05/29 00:00 [revised]
PHST- 2021/12/05 00:00 [received]
PHST- 2022/05/31 00:00 [accepted]
PHST- 2022/06/27 11:26 [entrez]
PHST- 2022/06/28 06:00 [pubmed]
PHST- 2022/06/30 06:00 [medline]
PHST- 2022/06/21 00:00 [pmc-release]
AID - IID3666 [pii]
AID - 10.1002/iid3.666 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2022 Jul;10(7):e666. doi: 10.1002/iid3.666.